title: Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy.
abstract: BACKGROUND
  Endoscopic therapies for early neoplasia in Barrett's esophagus may be a viable alternative to esophagectomy.
  
  
  OBJECTIVE
  Our purpose was to compare endoscopic therapy and esophagectomy.
  
  
  METHODS
  Retrospective review from a single institution.
  
  
  METHODS
  A medium-sized tertiary referral center.
  
  
  METHODS
  All patients with Barrett's esophagus and dysplasia or intramucosal carcinoma treated by photodynamic therapy (PDT), EMR, or argon plasma coagulation (APC) or esophagectomy with curative intent from May 1998 until November 2005.
  
  
  METHODS
  Survival, progression to cancer, eradication of dysplasia and Barrett's esophagus, major and minor complications, and costs were compared.
  
  
  RESULTS
  Sixty-two patients who underwent endoscopic therapy (2 APC alone, 18 EMR + APC, 20 PDT + APC, and 22 EMR + PDT + APC) and 32 patients who underwent esophagectomy met the inclusion criteria. The 30-day mortality rate included 1 patient in the endotherapy group (2%) and none in the surgical group (P = .49). No deaths from esophageal cancer occurred in either group. Cancer developed in 6% of endotherapy patients and in none in the surgical cohort (P < .05). Major and minor complications occurred in 8% and 31% of endotherapy patients, respectively, and 13% and 63% of surgery patients (P = .50, P < .001). Median cost to date was $40,079 for endotherapy and $66,060 for esophagectomy (P < .001).
  
  
  CONCLUSIONS
  Retrospective study, relatively short follow-up, small numbers.
  
  
  CONCLUSIONS
  Both endotherapy and esophagectomy can effectively treat high-grade dysplasia and intramucosal carcinoma associated with Barrett's esophagus. Endotherapy is associated with a higher risk of tumor progression, although this is uncommon. Esophagectomy incurs higher initial costs and results in more frequent minor complications but is usually curative.
authors.affiliation: Division of Gastroenterology, Virginia Mason Medical Center, Seattle, Washington 98101, USA.
authors.forename: Drew B
authors.initials: DB
authors.lastname: Schembre
authors.forename: Jasmine L
authors.initials: JL
authors.lastname: Huang
authors.forename: Otto S
authors.initials: OS
authors.lastname: Lin
authors.forename: Nico
authors.initials: N
authors.lastname: Cantone
authors.forename: Donald E
authors.initials: DE
authors.lastname: Low
mesh_terms: D000368:Aged; D001471:Barrett Esophagus / Q000473:pathology / Q000628:therapy*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D016099:Endoscopy, Gastrointestinal / Q000379:methods*; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017075:Laser Coagulation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010778:Photochemotherapy / Q000379:methods*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome